Barclays lowered the firm’s price target on Becton Dickinson (BDX) to $261 from $279 and keeps an Overweight rating on the shares. The firm updated its sum-of-the-parts analysis following reports that the company plans to separate its Bioscience and Diagnostics Solutions business. It cites a drop in peer multiples for the target cut.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDX:
- Gregory J. Hayes Joins Becton Dickinson Board
- Becton Dickinson announces first patient treated in GalaFLEX trial
- Tariff delay positive for Mexico-exposed medtech companies, says BofA
- Becton Dickinson recalls one lot of ChloraPrep Clear 1 mL applicators
- Becton Dickinson’s Hold Rating: Balancing Strong Financials with Strategic Uncertainty